The well-known pharmaceutical company Fu Pharma 360 million was sold.

Pharmaceutical Network August 7th - On August 5, Renfu Pharmaceutical Group Co., Ltd. ("HumanFu Pharmaceuticals") announced that it intends to transfer 70% of its stake in Sichuan Renfu Pharmaceutical Co., Ltd. to Chongqing Pharmaceuticals (Group) Co., Ltd. ("Heavy Pharmaceutical Group") for 362 million yuan. according to the
announcement, Renfu Pharmaceuticals and Heavy Pharmaceuticals Group signed the Equity Transfer Contract on August 5, 2020 (today) to transfer its 70% stake in Sichuan Renfu to The Heavy Pharmaceutical Group for 362 million yuan.
after the completion of this transaction, Sichuan Renfu will no longer be included in the scope of the company's consolidated statements.
is understood that heavy pharmaceutical group is based on pharmaceutical business, pharmaceutical research and development of cooperative development of enterprises, is the central and Chongqing two-level drug medical equipment fixed-point reserve units, but also operating narcotic drugs and the first class of psychotropic drugs of the national wholesale enterprises.
as of December 31, 2019, the Group's total assets were RMB2483,276 million, net assets of RMB734,459 million, and 2019 revenue was RMB33.84 billion and net profit was RMB930 million.
and Sichuan Renfu is a hospital drug sales, commercial distribution, medical equipment supplies sales and other business in one integrated pharmaceutical commercial company, the company under the jurisdiction of more than 10 holding subsidiaries, basically covering all levels of medical and health institutions in Sichuan Province.
, The company has actively promoted business focus and asset optimization in recent years, and has gradually exited segments where competitive advantages are not obvious or have weak synergies in the pharmaceutical industry, pharmaceutical commerce and medical services sectors.
the sale of 70% of Sichuan Renfu, the company will generate a non-recurring loss of about 26 million yuan in the current trading period, while the company will receive 362 million yuan in equity transfer, recover Sichuan Renfu and its subsidiaries to borrow about 300 million yuan and reduce interest-bearing debt of about 1 billion yuan, which is conducive to the company to further optimize the asset and liability structure, focus resources to develop competitive areas, in line with the company's development strategy and long-term interests.
, the non-core business data show that in recent years, The asset-liability ratio of Renfu Pharmaceuticals has continued to rise, in 2017-2019, the company's asset-liability ratio is 53.1%, 59.7%, 60.02%.
by 2019, the total liabilities of Renfu Pharmaceuticals have reached 21.016 billion yuan.
in order to reduce the ratio of assets and liabilities, after 2017, Renfu Pharmaceuticals has launched a "denuclearization" strategy, gradually divesting non-core pharmaceutical assets, focusing on the core pharmaceutical industry, cash withdrawal, 17 years to recover 3.4 billion funds, 18 years to recover 2 billion funds.
According to China Industrial Economic Information Network statistics, since 2019, the company has sold 100% of Henan Renfu Pharmaceutical Co., Ltd., Wuhan Yimei Lidide Biopharmaceutical Co., Ltd. 100% of the equity, Wuhan People's Fulea Oral Clinic Co., Ltd. 70% of the equity, Beijing Mano Biopharmaceutical Co., Ltd. 33% equity and Zhongxiang City People's Hospital New Hospital District real estate and other assets, the cumulative recovery of assets transfer of about 900 million yuan.
research institutions believe that 2020 is expected to be the year of naturalization of HumanFu Pharmaceuticals, non-core asset divestiture or can recover 10 billion cash, in addition to divestiture assets landing projects, a number of non-core divestitures in the asset appraisal audit or price negotiations, or will land in 2020.
in the long run, non-core pharmaceutical assets, including commercial and other financial assets, may also be sold.
as the leader of domestic anaesthetic analgesics, 2017 "nuclearization" strategy has been implemented, the thinking of people-fu medicine gradually focused on the industry has been clear, the current formation of narcotic drugs (Yichang Manfu), the pharmaceutical industry (Wuhan People's Fu, Gedian Manfu, Xinjiang Vimedicine), international business (U.S. generic drugs, preparation exports) and gender health (Leforth) four major sectors.
HumanFu Pharmaceuticals 2019, the company and its subsidiaries have 566 pharmaceutical production approvals, including 37 exclusive product s/he products, 152 products are included in the national base drug catalog, 302 products are included in the national health insurance catalog, and more than 80 FDA-approved ANDA numbers are available.
according to the annual report data, the company has set up a regional pharmaceutical business network in Hubei Province, Sichuan Province, engaged in the distribution of pharmaceutical products, distribution and related business.
companies under the pharmaceutical commercial subsidiaries can be divided into provincial companies and municipal companies two levels, provincial companies for management and procurement platform, municipal companies responsible for improving the terminal sales network, to undertake provincial company business, to achieve unified purchase and distribution, to provide medical institutions at all levels of medicine, equipment, medical equipment, reagents, supplies, health products, technology and management services.
the sale of Sichuan Renfu, under the jurisdiction of more than a dozen holding subsidiaries, basically covering all levels of medical and health institutions in Sichuan Province.
or can reflect the relevant ideas of the competitive advantage of people-fu pharma exiting the business without obvious subdivision.
Heavy Drug Holdings, continue to expand the national market Heavy Pharmaceutical Group is the only subsidiary of Heavy PharmaceuticalS Holdings, formerly established in 1950, the Chinese pharmaceutical company Southwest Division Company.
it is understood that the heavy drug holding business has covered 31 provinces (municipalities and autonomous regions), set up 14 pharmaceutical commercial provincial platform, in the core sales area of Chongqing City, has achieved the full coverage of tertiary A medical institutions, the basic coverage of secondary hospitals, Chongqing city more than two levels (including secondary) medical institutions coverage of more than 80%.
and heavy drug holdingto to expand sales areas, accelerate the pace of national network layout has already begun. On June 28,
, Tianshili (600535) issued a revised version of the major asset sale report (draft), and six partnerships, including Tianjin Shanxuan, Tianjin Zhiyi, Tianjin Ruizhang, Tianjin Yanxiang, Tianjin Rui and Tianjin Yanlong, which are indirectly controlled, intend to sell 99.9448% of Tianshi Marketing to Chongqing Pharmaceuticals.
, Tianshili intends to sell 88.4937% of Tianshi Marketing to Chongqing Pharmaceuticals, and six partnerships under its indirect control intend to sell its total 11.4511% stake in Tianshi Marketing to Chongqing Pharmaceuticals.
the target of this transaction, Tianshi Marketing is one of the main sources of Tianshi's operating income, in 2019 Tianli marketing revenue of 13.435 billion yuan, accounting for 70.72 percent of Tianshili's total operating income (18.998 billion yuan).
through the acquisition of Tianshili marketing, heavy drug holdings can access all its channels, resources and markets, into Shanxi, Shaanxi, Beijing, Liaoning, Tianjin, Shandong, Hunan and Guangdong market hinterland.
and this acquisition of Sichuan People's Fu, it also took its Sichuan commercial channels, Chongqing Pharmaceutical's national map, and then the next city.
.